Oxidative Medicine and Cellular Longevity

Oxidative Medicine and Cellular Longevity / 2019 / Article
Special Issue

New Trends in Antioxidant Compounds: A Precise Nutraceutical in Cardiometabolic Disorders

View this Special Issue

Research Article | Open Access

Volume 2019 |Article ID 8184656 | 11 pages | https://doi.org/10.1155/2019/8184656

Anti-inflammatory Role of Carotenoids in Endothelial Cells Derived from Umbilical Cord of Women Affected by Gestational Diabetes Mellitus

Academic Editor: Mariateresa Giuliano
Received09 Aug 2018
Accepted10 Dec 2018
Published30 Jan 2019

Abstract

Diabetes is associated with vascular inflammation, endothelial dysfunction, and oxidative stress, promoting the development of cardiovascular diseases (CVD). Several studies showed that a carotenoid-rich diet is associated to a reduced cardiovascular risk in healthy and diabetic subjects, although the mechanisms of action are still unknown. Here, the potential role of β-carotene (BC) and lycopene (Lyc) in human endothelial cells isolated from human umbilical cord vein (HUVECs) of women with gestational diabetes (GD) and respective controls (C) has been investigated. Results showed that BC and Lyc reduced the tumor necrosis factor alpha- (TNF-α-) stimulated monocyte-endothelium interaction (adhesion assay), membrane exposure (flow cytometry), and total expression levels (Western blot) of VCAM-1 and ICAM-1 in both cell types. Moreover, the treatment with BC and Lyc reduced the TNF-α-induced nuclear translocation of NF-κB (image flow cytometry) by preserving bioavailability of nitric oxide (NO, flow cytometry, and cGMP EIA kit assay), a key vasoactive molecule. Notably, BC and Lyc pretreatment significantly reduced peroxynitrite levels (flow cytometry), contributing to the redox balance protection. These results suggest a new mechanism of action of carotenoids which exert vascular protective action in diabetic condition, thus reinforcing the importance of a carotenoid-rich diet in the prevention of diabetes cardiovascular complications.

1. Introduction

Cardiovascular diseases represent the major complications and the main cause of reduced life expectancy in type 2 diabetic patients [1].

Diabetes is a chronic low-grade inflammatory condition featured by the increased plasma levels of TNF-α, a primary mediator of inflammation and insulin resistance [2], and reactive oxygen species (ROS), both playing an important role in the promotion of endothelial dysfunction and cardiovascular complications [3].

Nitric oxide is an important molecule playing a pleiotropic role in preserving vascular wall homeostasis. It is produced by endothelial nitric oxide synthase (eNOS) via the conversion of the amino acid L-arginine into L-citrulline. Once released, it diffuses to the vascular smooth muscle cells (vSMC), where it activates the enzyme guanylate cyclase (GC), inducing the production of cyclic guanosine monophosphate (cGMP), a molecule involved in vascular relaxation. Moreover, nitric oxide (NO) modulates platelet aggregation and monocyte adhesion and infiltration into the vascular wall and inhibits vSMC proliferation and migration [4, 5]. Thus, the maintenance of nitric oxide availability is mandatory to avoid the activation of the inflammatory process and the endothelial dysfunction.

However, several studies found that under hyperglycemic conditions NO rapidly reacts with superoxide anion (O2•−) to form peroxynitrite (ONOO), a highly potent oxidant molecule that diffuses across phospholipid membranes, resulting in substrate nitrosylation and nitric oxide bioavailability decline [68].

Several natural molecules seem to have a beneficial effect on oxidative stress and vascular dysfunction [911]; among them, carotenoids are the most characterized. Carotenoids include a large family of fat-soluble molecules noted for their antioxidant action [12]. However, besides their antioxidant effect, they also exert an anti-inflammatory effect, playing an important role in the prevention of cardiovascular complications [13, 14].

Among more than 700 carotenoids discovered, the main and better characterized are β-carotene and lycopene with free radical scavenger activity and nutritional relevance [15]. Interestingly, several studies showed that carotenoids are able not only to prevent but also to ameliorate diabetes and its subsequent complications by reducing oxidative stress [16, 17].

In preclinical reports using streptozotocin- (STZ-) induced hyperglycemic rats as a model to evaluate the effect of chronic lycopene treatment [1820], it was found that this molecule acts as an antidiabetic agent, attenuating endothelial dysfunction by its antioxidant action.

Moreover, other studies also indicated that dietary lycopene administration markedly reduced serum lipid levels and the formation of atherosclerotic plaques in New Zealand White (NZW) rabbits fed a high-fat diet [2123], further indicating that lycopene could play a significant role in the prevention of cardiovascular consequences.

As regard human studies, although the evidence on the beneficial effects of carotenoids in the reduction of diabetes incidence is controversial [2426], it was demonstrated that serum concentration of carotenoids was inversely associated with future oxidative stress, inflammation, and endothelial dysfunction [27]. In addition, prospective investigations highlighted that adequate dietary intakes of carotenoids were associated with a reduced risk for type 2 diabetes mellitus (T2DM) [2830], inducing to establish a “carotenoid health index” to better evaluate the cardiovascular risk according to established plasmatic carotenoid concentrations [31].

Although several in vitro cellular models have been used to evaluate the role of carotenoids in reducing the development and the progression of the atherosclerotic plaque [17, 32, 33], it is however mandatory to better delineate the molecular events involved in the beneficial effect of carotenoids in slowing down the endothelial dysfunction and the atherosclerotic process in diabetes mellitus.

In this study, we used an endothelial cell model of chronic hyperglycemia derived from the human umbilical cord vein of women affected by gestational diabetes (GD-HUVECs). Recently, we found that these cells exhibit durable proatherogenic modifications of cellular homeostasis potentially predisposing to endothelial dysfunction and atherosclerosis development [34, 35], making them a useful model for studying endothelial dysfunction related to diabetes. Thus, we aim to investigate the molecular mechanisms of new natural molecules such as β-carotene and lycopene on the prevention or the delay of the vascular damage induced by hyperglycemia.

In particular, to better outline the way of action of carotenoids in endothelial dysfunction prevention in diabetes, we pretreated TNF-α-stimulated GD-HUVECs with β-carotene and lycopene. Interestingly, we found that the exposure of diabetic HUVECs to β-carotene and lycopene resulted in an increased nitric oxide bioavailability, probably induced by the scavenging action of carotenoids, and in the reduction of the oxidative and inflammatory stress damage.

2. Materials and Methods

2.1. Materials

Phosphate-buffered saline (PBS, CAT. D8662), Dulbecco’s modified Eagle medium (DMEM, CAT. D6046), M199 endothelial growth medium (CAT. M4530), 0.5% trypsin/0.2%, ethylenediaminetetraacetic acid (EDTA) solution (CAT. 59418C), bovine serum albumin (BSA), L-glutamine (CAT. G7513), penicillin-streptomycin (CAT. P4333), phorbol myristate acetate (PMA, CAT. P1585), ionomycin (Iono, CAT. I0634), anti-β-actin mouse monoclonal antibody (CAT. A5441), 7-aminoactinomycin D (7-AAD, CAT. A9400), and TNF-α (CAT. T0157) were purchased from Sigma-Aldrich (Saint Louis, USA). Fetal bovine serum (FBS, CAT. 41A0045K) was from Life Technologies (Monza, Italy), and L-nitro-arginine-methyl ester (L-NAME, CAT. ALX-105-003) was purchased from Alexis Biochemicals (San Diego, CA, USA). Anti-vascular cell adhesion molecule-1 (VCAM-1, CAT. sc-13160) and anti-intercellular adhesion molecule-1 (ICAM-1, CAT. sc-107) antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). PE-labeled anti-VCAM-1 (phycoerythrin-labeled, CAT. 305806) and FITC-labeled anti-ICAM-1 (fluorescein isothiocyanate-labeled, CAT. 313104) antibodies were from BioLegend (San Diego, CA, USA). Anti-NF-κB p65 (CAT. 4764) primary antibody was from Cell Signaling (Danvers, MA, USA). Alexa Fluor 488-conjugated antibody was from Invitrogen (CAT. 11034). DAF-2DA probe was from Calbiochem (CAT. 251505). HKGreen-4A was synthesized by Prof. Dan Yang’s lab [36]. An enzyme immunoassay (EIA) kit was taken from GE Healthcare (Little Chalfont, Buckinghamshire, UK). Lycopene (Lyc, CAT. L9879) was purchased from Sigma-Aldrich, and β-carotene (BC, CAT. 22040) from Fluka (Hamburg, Germany): both were dissolved in tetrahydrofuran (THF, CAT. 401757, Sigma-Aldrich) and used as described in our previous work [37].

2.2. Cell Cultures and Experimental Protocol

Primary human umbilical vein endothelial cells (HUVECs) were explanted by umbilical cords obtained from randomly selected mothers affected by gestational diabetes (GD) and healthy Caucasian mothers (Control, C), according to the previously reported methods [38]. The characteristics of C-mothers () and GD-mothers () selected for this work are described in Table 1. All procedures were in agreement with the ethical standards of the Institutional Committee on Human Experimentation (reference number 1879/09COET) and with the Declaration of Helsinki principles. For experiments, C- and GD-HUVECs were grown to subconfluence in a DMEM/M199 medium (ratio 1 : 1) supplemented with 20% FBS, 10 μg/mL heparin and 50 μg/mL endothelial cell growth factor. Serum-starved cells (in medium with 0.5% FBS) were incubated with TNF-α at concentration 1 ng/mL for 16 hours, following 24-hour preincubation with β-carotene or lycopene (2.5 μmol/L).


CharacteristicC-womenGD-women

Age (years)35 ± 7.134 ± 5.67
Height (cm)163.75 ± 5.66162.4 ± 7.93
Pregestational weight (kg)68.14 ± 1367.1 ± 10.73
BMI (kg/m2)27.49 ± 5.1827.81 ± 2.97
OGTT values (mmol/L)
Basal glycaemia4.5 ± 0.245.1 ± 0.24
1 h glycaemia8.1 ± 0.9910.2 ± 1.16
2 h glycaemia6.54 ± 1.148.04 ± 1.71
OGTT gestational week27.9 ± 2.424.4 ± 4.7
SBP (mm/Hg)107.6 ± 8.87105.5 ± 10.7
DBP (mm/Hg)71.4 ± 9.168.4 ± 10.57

Data are expressed as the mean ± SD. BMI: body mass index, OGTT: oral glucose tolerance test, SBP: systolic blood pressure, DBP: diastolic blood pressure. ; .

All experiments were performed in technical duplicate or triplicate using at least 3 different cellular strains () obtained from umbilical cords of C- or GD-women.

2.3. Monocyte-HUVEC Adhesion Assays

The adhesion assay was performed in C- and GD-HUVECs in the basal state and after incubation for 24 hours with BC or Lyc (2.5 μmol/L) before stimulation with or without 1 ng/mL TNF-α for 16 hours. The cells were grown to confluence in six-well tissue culture plates and U937 cell lines (European Collection of Authenticated Cell Cultures (ECACC)) were used to evaluate the adhesion to HUVEC monolayers as previously described [39]. One hour before the assay, HUVECs were treated with antibodies against VCAM-1 or ICAM-1 at saturating concentrations (1 μg/1 × 106 cells) as negative technical controls. Photos were randomly chosen high-power fields taken at a half-radius distance from the centre of the well in one of three comparative experiments of a similar design, showing U937 monocytoid cell adhesion to endothelial cells.

2.4. Western Blot Analysis

C- and GD-HUVECs were stimulated as described in the experimental protocol, and Western blot analysis was performed as previously described [10]. For the specific experiment, cells were lysed and 30 μg total protein was resolved by SDS-PAGE, transferred to nitrocellulose membrane, and immunoblotted using mouse monoclonal anti-VCAM-1 and ICAM-1 (1 : 1000 and 1 : 500, respectively) and mouse monoclonal anti-β-actin (1 : 10.000). The membranes were then incubated with peroxidase-conjugated secondary antibodies (1 : 10.000). Band densities of proteins were detected and quantified by using the Alliance Chemiluminescence Imaging System (UVItec Limited, Cambridge, United Kingdom). Densities of VCAM-1 and ICAM-1 proteins were divided by those of β-actin content, and the ratio was indicated as arbitrary units.

2.5. cGMP EIA Kit Assay

Control and GD-HUVECs were grown to confluence in six-well tissue culture plates and were stimulated as described in the experimental protocol. To stimulate endogenous NO production, C- and GD-HUVECs were incubated with ionomycin (2 μmol/L for 24 h) with or without L-NAME preincubation (1 mmol/L for 45 minutes). Intracellular cGMP levels were evaluated by using a commercial enzyme immunoassay (EIA) kit, following the instruction provided by the supplier.

2.6. Flow Cytometry Analysis

At the basal state and after stimulations, nonpermeabilized cells were detached by 5 mM EDTA, washed, and resuspended in 0.5% BSA solution. Cells were treated and incubated with anti-VCAM-1 PE conjugate (1 : 100) and with anti-ICAM-1 FITC conjugate (1 : 100) as previously described [38]. To determine cytoplasm-nucleus translocation of NF-κB p65, cells were permeabilized by an Intrasure kit (CAT. 641778, BD Biosciences), processed, and incubated with anti-NF-κB p65 (1 : 100) primary antibody and then secondary antibody Alexa 488 conjugate (1 : 100). Nuclear staining was performed by incubating the cells with 7-AAD (1 : 100) for 10 minutes at room temperature, and all samples were analysed by imaging flow cytometry (ImageStream AMNIS by using IDEAS software, BD).

To evaluate NO levels, 5 × 105 C- and GD-HUVECs were incubated with the cell-permeable fluorescent nitric oxide probe DAF-2DA (2 μmol/L for 30 minutes at 37°C). For the evaluation of intracellular levels of peroxynitrite (ONOO), about 5 × 105 cells were incubated with the HKGreen-4A probe as previously described [38]. 10.000 events for each sample were analysed using a FACS Calibur or FACS Canto II flow cytometer (BD Bioscences, California, USA). All data were analysed using FACS Diva (BD Bioscences), FlowJo v.8.8.6 (TreeStar, Ashland, OR), and CELL Quest 3.2.1 software (BD Biosciences).

All results are expressed as the percentage (%) of positive cells or the MFI (mean fluorescence intensity) ratio, calculated by dividing the MFI of positive events by the MFI of negative events (MFI of secondary antibody).

2.7. Statistical Analysis

Results are presented as the deviation (SD) of at least 3 different experiments using at least 3 different cellular strains () both of C-HUVECs and of GD-HUVECs. Student’s -test and ANOVA test followed by the Bonferroni multiple comparison test for post hoc comparisons were used to analyse the differences between the two cell strains and between the different treatments. Significance was defined as a value less than 0.05.

3. Results

3.1. Effect of Carotenoids on Monocyte-HUVEC Interaction

The effects of carotenoids on human monocyte line U937 adhesion rate to control and GD-HUVECs, in basal or TNF-α-stimulated conditions, were investigated.

Figure 1 shows that, in the basal state, the monocyte-GD-HUVEC interaction was significantly higher compared to C-HUVECs (). The exposure to 1 ng/mL TNF-α further increased this difference (). Interestingly, pretreatment with 2.5 μmol/L of BC or Lyc for 24 hours significantly resulted in the reduction of monocyte adhesion induced by TNF-α to both cell types ().

3.2. Effect of Carotenoids on Adhesion Molecule Membrane Exposure and Expression

The exposure of the adhesion molecules on the endothelial cell membrane is the major mechanism responsible for the monocyte-endothelial cell interaction. We thus evaluated VCAM-1 and ICAM-1 membrane exposure and total protein expression in C- and GD-HUVECs with or without the pretreatment with BC or Lyc (2.5 μmol/L for 24 h) and in the presence or absence of the inflammatory stimulus TNF-α.

Figure 2 shows that both basal VCAM-1 (Figure 2(a)) and ICAM-1 (Figure 2(b)) exposure is greater on GD-HUVEC membrane compared to control cells ( and , respectively). TNF-α increased the exposure of VCAM-1 and ICAM-1 in both cell types (). The increased exposure induced by TNF-α was significantly reduced in the presence of 2.5 μmol/L for 24 h BC or Lyc (). Interestingly, in GD-HUVECs, Lyc is able to reduce ICAM-1 exposure on the endothelial membrane also in the basal state ().

After 16 h of 1 ng/mL TNF-α stimulation, a significant increase in VCAM-1 (Figure 2(c)) and ICAM-1 (Figure 2(d)) total protein levels was observed. The increase was more pronounced in GD-HUVECs as compared to C-HUVECs (). Remarkably, in TNFα-stimulated C- and GD-HUVECs, the pretreatment with 2.5 μmol/L for 24 h of BC (left) or Lyc (right) significantly decreased adhesion molecule protein levels (), supporting the idea of the potential role played by these carotenoids in the reduction of the monocyte adhesion.

3.3. Effect of Carotenoids on NF-κB p65 Nuclear Translocation

Figure 3 shows the nucleus-NF-κB p65 colocalization rate expressed as the histogram (Figure 3(a)) and single-cell images (Figure 3(b)) in the presence or absence of BC and Lyc (2.5 μmol/L for 24 h) in C- and GD-HUVECs with or without the inflammatory stimulus TNF-α.

As expected, compared to C-HUVECs, GD-HUVECs at basal condition showed an enhanced NF-κB p65 nuclear translocation level (), which was further significantly increased following TNF-α stimulation in both cell types (), and it resulted to be more evident in GD-HUVECs ( vs. C-HUVECs). Interestingly, 24 h pretreatment with BC or Lyc was associated to a significant reduction of TNF-α-induced NF-κB nuclear translocation in both GD- and C-HUVECs (). It is noteworthy how in BC and Lyc pre-treated control cells a reduction of NF-κB nuclear translocation was also evident in basal condition.

3.4. Effect of Carotenoids on NO Bioavailability

As shown in Figure 4, as compared to basal condition, TNF-α stimulation significantly decreased nitric oxide levels both in C- and in GD-HUVECs (). Pretreatment with 2.5 μmol/L β-carotene and lycopene restored NO bioavailability in both the cell types. Moreover, after TNF-α exposure, both the cell types displayed decreased levels of cGMP, a biological target of NO activity, compared to their basal condition, and this was more evident in GD-HUVECs (). Notably, cGMP content significantly increased after pretreatment with BC and Lyc in both TNF-α-stimulated C-HUVECs and TNF-α-stimulated GD-HUVECs (). As a positive control, eNOS activator ionomycin (Iono) stimulation was used and a significant increase in nitric oxide bioavailability and cGMP levels () was observed in C-HUVECs, the effect that was abolished by the preincubation with the eNOS inhibitor L-NAME ().

3.5. Effect of Carotenoids on Peroxynitrite Production

To better understand if the increased NO levels after BC and Lyc stimulation were associated with a reduced peroxynitrite formation, we evaluated the intracellular ONOO production in C- and GD-HUVECs in the presence or absence of an inflammatory stimulus.

Figure 5 shows that, in the basal state, GD-HUVECs display greater peroxynitrite levels compared to C-HUVECs (). The pretreatment with 2.5 μmol/L of BC or Lyc for 24 h decreased the peroxynitrite levels in both TNFα-stimulated cell types. This result is more evident in GD-HUVECs (). The potent oxidant molecule PMA (200 ng/mL) and Ionomycin (50 nmol/L) pretreatment for 30 minutes highly increased the percentage of positive cells for peroxynitrite probe (), mostly in control with respect to GD-HUVECs, confirming the efficiency of the assay.

4. Discussion

Cardiovascular complications are the major consequences of chronic hyperglycemia and represent the main reason for impaired life expectancy in diabetic patients [40]. In fact, cardiovascular events represent the most prevalent cause of morbidity and mortality in diabetic patients [40]; thus, an optimal control of both hyperglycemia and cardiovascular risk factors is necessary to prevent adverse outcomes in type 2 diabetic patients [41]. More in depth knowledge of the complex of mechanisms controlling vascular damage in diabetes suggested that some natural molecules could be able to address multiple aspects of diabetes and its complications and, most importantly, to reduce disease-related morbidity and mortality [14].

Although several studies have been performed regarding the potential protective role of some natural antioxidant molecules, disparate results have been obtained regarding the beneficial effect of antioxidant therapy in the reduction of diabetes incidence and the prevention of its cardiovascular complications [42].

Carotenoids are among the main characterized natural antioxidants studied in order to find new potential protective molecules for chronic inflammation and oxidative stress [12]. However, controversial data have been found on their effects. Indeed, it is likely that the structure of carotenoids makes these molecules highly susceptible to oxidation under certain conditions, such as the oxygen partial pressure (PO2) and their high amount [4346], inducing a reduction in their nutritional value and their beneficial action [47, 48].

In addition, several studies also showed that the mechanisms of action and the antioxidant capacities of carotenoids could be totally different and strongly dependent upon their interaction with other antioxidant compounds [49]. Indeed, an increase in the concentration of one might reduce the absorption of another with a great antioxidant capacity reducing the overall effectiveness [50]. In fact, the effect of antioxidant molecules has to be considered the result of a complex network involving several reactive species and other biological targets, and the redox regulation has to consider not only the ROS imbalance in a quantitative manner but also their chemical structure, cellular location, formation and degradation rate, and physiological functions [51]. Furthermore, the presence of chemical interactions between reactive oxygen species, which influence the response of organism to environmental challenges and stressors ensuring its homeostasis, must be considered. Then, it is necessary not to discard the idea that inappropriate removal of ROS could be also be self-defeating [52].

Hence, there is still not a definite scenery regarding the potential benefic effect of carotenoid diet administration in diabetes cardiovascular complication prevention and their mechanism of action, so further analyses are needed.

In the present study, we investigated the mechanisms potentially involved in carotenoid prevention of vascular inflammation and atherogenesis under chronic hyperglycemic condition.

In particular, we evaluated the effect of β-carotene and lycopene on the modulation of the inflammatory and nitro-oxidative state of GD-HUVECs, which represent a useful cellular model of endothelial dysfunction occurring during hyperglycemic conditions [34]. Cells were exposed in vitro to β-carotene and lycopene concentration comparable to circulating levels of those molecules reached after oral administration, in vivo.

The results obtained suggest a new hypothesis regarding the mechanism of action of carotenoids in the prevention of diabetes-related cardiovascular complications.

At first, in order to evaluate carotenoids’ anti-inflammatory action, we determined the monocyte-endothelial cell interaction rate, finding that β-carotene and lycopene significantly reduced monocyte-HUVEC adhesion in TNF-α-stimulated C- and GD-HUVECs (Figure 1). Coherently, we also observed that BC and Lyc significantly decreased TNF-α-induced VCAM-1 and ICAM-1 membrane exposure and the total protein expression in both control and GD cells (Figure 2).

Moreover, it is noted that NF-κB plays a fundamental role in the expression of proinflammatory molecules such as cytokines, chemokine, and adhesion molecules [53] and several studies demonstrated that it is highly involved in metabolic disorders and atherosclerosis [54, 55], thus evaluating the effect of carotenoids treatment on NF-κB nuclear translocation.

Interestingly, we found that, under a TNF-α-stimulated state, carotenoid treatment significantly reduced NF-κB nuclear translocation in control cells as well as in GD-endothelial cells (Figure 3). Notably, these data highlight the ability of carotenoids to inhibit the inflammatory pathway not only in healthy conditions, as previously found [37], but also in a hyperglycemic state, suggesting their anti-inflammatory role in diabetes.

In this regard, we consider the effect of BC and Lyc pretreatment in the modulation of nitric oxide bioavailability, which is involved in the modulation of the NF-κB pathway [56] and thus in the vascular homeostasis balance.

Of note, in endothelial cells chronically exposed to high glucose and inflammation, despite an increase in NO production [57], the bioavailability of nitric oxide is decreased, as we previously demonstrated [34], probably as results of the “quenching” of NO, which rapidly reacts with the high levels of superoxide to produce peroxynitrite [58].

Here, we further confirm that the exposition to the proinflammatory stimulus TNF-α promotes a decline in NO levels and a decrease of the production of cGMP, its biological target, both in C- and in GD-HUVECs (Figure 4). However, remarkably, we also found that the exposure to β-carotene and lycopene induced an increase in NO bioavailability, particularly in GD-HUVECs.

In this regard, not surprisingly, the pretreatment with BC and Lyc resulted in the decreased peroxynitrite production in both TNF-α-exposed control and GD-HUVECs (Figure 5), confirming their antioxidant action and their role in the promotion of nitric oxide level maintenance.

All together, these results indicate that carotenoids contribute to restore endothelial homeostasis in an endothelial cell model chronically exposed to high-glucose levels by promoting nitric oxide bioavailability, exerting both antioxidant and anti-inflammatory actions.

5. Conclusion

In conclusion, data obtained in the present study elucidate the mechanisms of action of carotenoids in the modulation of the inflammatory and oxidative state induced in vitro by the proinflammatory molecule TNF-α on an endothelial cellular model of chronic hyperglycemia.

Then, while care must be taken regarding the safety of chronic and high-dose carotenoid supplementation, our results show that a diet amount administration of these natural food components could be important for the management of the vascular homeostasis in hyperglycemic conditions, speculating that a carotenoid-rich diet could prevent cardiovascular complications in diabetic patients.

Data Availability

The experimental data and materials used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contributions

MU, PDT, and AP conceived and designed the experiments. MU, PDT, FT, VGPC, GB, and SDS performed the experiments. MU, PDT, PL, NDP, CP, and DM analysed the data. MU, PDT, GF, and AP drafted the paper. All authors read and approved the final manuscript. Mariangela Ucci and Pamela Di Tomo contributed equally to this work.

Acknowledgments

This work was supported by grant SAper NutrIre (SANI) from the POR FESR ABRUZZO 2014-2020 Asse I Determinazione no. 39 DPG013 del 22/12/2017 (AP).

References

  1. I. M. Stratton, A. I. Adler, H. A. Neil et al., “Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study,” The BMJ, vol. 321, no. 7258, pp. 405–412, 2000. View at: Publisher Site | Google Scholar
  2. J. P. Kirwan, S. Hauguel-de Mouzon, J. Lepercq et al., “TNF-α is a predictor of insulin resistance in human pregnancy,” Diabetes, vol. 51, no. 7, pp. 2207–2213, 2002. View at: Publisher Site | Google Scholar
  3. H. C. Gerstein, J. Pogue, J. F. E. Mann et al., “The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis,” Diabetologia, vol. 48, no. 9, pp. 1749–1755, 2005. View at: Publisher Site | Google Scholar
  4. A. Pandolfi and E. A. De Filippis, “Chronic hyperglicemia and nitric oxide bioavailability play a pivotal role in pro-atherogenic vascular modifications,” Genes & Nutrition, vol. 2, no. 2, pp. 195–208, 2007. View at: Publisher Site | Google Scholar
  5. J. Davignon and P. Ganz, “Role of endothelial dysfunction in atherosclerosis,” Circulation, vol. 109, 23 Supplement 1, pp. III27–III32, 2004. View at: Publisher Site | Google Scholar
  6. H. Cai and D. G. Harrison, “Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress,” Circulation Research, vol. 87, no. 10, pp. 840–844, 2000. View at: Publisher Site | Google Scholar
  7. C. E. Tabit, W. B. Chung, N. M. Hamburg, and J. A. Vita, “Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications,” Reviews in Endocrine & Metabolic Disorders, vol. 11, no. 1, pp. 61–74, 2010. View at: Publisher Site | Google Scholar
  8. D. Jourd'heuil, F. L. Jourd'heuil, P. S. Kutchukian, R. A. Musah, D. A. Wink, and M. B. Grisham, “Reaction of superoxide and nitric oxide with peroxynitrite: implications for peroxynitrite-mediated oxidation reactions in vivo,” Journal of Biological Chemistry, vol. 276, no. 31, pp. 28799–28805, 2001. View at: Publisher Site | Google Scholar
  9. C. A. Schmitt and V. M. Dirsch, “Modulation of endothelial nitric oxide by plant-derived products,” Nitric Oxide, vol. 21, no. 2, pp. 77–91, 2009. View at: Publisher Site | Google Scholar
  10. P. Di Tomo, S. Di Silvestre, V. G. P. Cordone et al., “Centella Asiatica and lipoic acid, or a combination thereof, inhibit monocyte adhesion to endothelial cells from umbilical cords of gestational diabetic women,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 25, no. 7, pp. 659–666, 2015. View at: Publisher Site | Google Scholar
  11. M. G. Scioli, A. Bielli, S. Agostinelli et al., “Antioxidant treatment prevents serum deprivation-and TNF-α-induced endothelial dysfunction through the inhibition of NADPH oxidase 4 and the restoration of β-oxidation,” Journal of Vascular Research, vol. 51, no. 5, pp. 327–337, 2014. View at: Publisher Site | Google Scholar
  12. L. H. Skibsted, “Carotenoids in antioxidant networks. Colorants or radical scavengers,” Journal of Agricultural and Food Chemistry, vol. 60, no. 10, pp. 2409–2417, 2012. View at: Publisher Site | Google Scholar
  13. S. Voutilainen, T. Nurmi, J. Mursu, and T. H. Rissanen, “Carotenoids and cardiovascular health,” The American Journal of Clinical Nutrition, vol. 83, no. 6, pp. 1265–1271, 2006. View at: Publisher Site | Google Scholar
  14. K. Yamagata, Carotenoids Regulate Endothelial Functions and Reduce the Risk of Cardiovascular Disease, Carotenoids: InTech, 2017. View at: Publisher Site
  15. A. V. Rao and L. G. Rao, “Carotenoids and human health,” Pharmacological Research, vol. 55, no. 3, pp. 207–216, 2007. View at: Publisher Site | Google Scholar
  16. A. Roohbakhsh, G. Karimi, and M. Iranshahi, “Carotenoids in the treatment of diabetes mellitus and its complications: a mechanistic review,” Biomedicine & Pharmacotherapy, vol. 91, pp. 31–42, 2017. View at: Publisher Site | Google Scholar
  17. B. Kulczyński, A. Gramza-Michałowska, J. Kobus-Cisowska, and D. Kmiecik, “The role of carotenoids in the prevention and treatment of cardiovascular disease–current state of knowledge,” Journal of Functional Foods, vol. 38, pp. 45–65, 2017. View at: Publisher Site | Google Scholar
  18. M. M. Ali and F. G. Agha, “Amelioration of streptozotocin-induced diabetes mellitus, oxidative stress and dyslipidemia in rats by tomato extract lycopene,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 69, no. 3, pp. 371–379, 2009. View at: Publisher Site | Google Scholar
  19. D. E. Ejike, M. A. Adam, O. S. Sheu et al., “Lycopene attenuates diabetes-induced oxidative stress in Wistar rats,” Journal of Diabetes and Endocrinology, vol. 9, no. 2, pp. 11–19, 2018. View at: Publisher Site | Google Scholar
  20. J. Zhu, C. G. Wang, and Y. G. Xu, “Lycopene attenuates endothelial dysfunction in streptozotocin-induced diabetic rats by reducing oxidative stress,” Pharmaceutical Biology, vol. 49, no. 11, pp. 1144–1149, 2011. View at: Publisher Site | Google Scholar
  21. M. Verghese, J. Richardson, J. Boateng et al., “Dietary lycopene has a protective effect on cardiovascular disease in New Zealand male rabbits,” Journal of Biological Sciences, vol. 8, no. 2, pp. 268–277, 2008. View at: Publisher Site | Google Scholar
  22. S. A. Mulkalwar, N. S. Munjal, U. More, B. More, A. B. Chaudhari, and P. R. Dewda, “Effect of purified lycopene on lipid profile, antioxidant enzyme and blood glucose in hyperlipidemic rabbits,” American Journal of PharmTech Research, vol. 2, pp. 461–470, 2012. View at: Google Scholar
  23. M.-Y. Hu, Y.-L. Li, C.-H. Jiang, Z. Q. Liu, S. L. Qu, and Y. M. Huang, “Comparison of lycopene and fluvastatin effects on atherosclerosis induced by a high-fat diet in rabbits,” Nutrition, vol. 24, no. 10, pp. 1030–1038, 2008. View at: Publisher Site | Google Scholar
  24. L. Wang, S. Liu, A. D. Pradhan et al., “Plasma lycopene, other carotenoids, and the risk of type 2 diabetes in women,” American Journal of Epidemiology, vol. 164, no. 6, pp. 576–585, 2006. View at: Publisher Site | Google Scholar
  25. A. J. M. Cooper, S. J. Sharp, R. N. Luben, K. T. Khaw, N. J. Wareham, and N. G. Forouhi, “The association between a biomarker score for fruit and vegetable intake and incident type 2 diabetes: the EPIC-Norfolk study,” European Journal of Clinical Nutrition, vol. 69, no. 4, pp. 449–454, 2015. View at: Publisher Site | Google Scholar
  26. A. Ceriello, R. Testa, and S. Genovese, “Clinical implications of oxidative stress and potential role of natural antioxidants in diabetic vascular complications,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 26, no. 4, pp. 285–292, 2016. View at: Publisher Site | Google Scholar
  27. A. Hozawa, D. R. Jacobs, M. W. Steffes, M. D. Gross, L. M. Steffen, and D. H. Lee, “Relationships of circulating carotenoid concentrations with several markers of inflammation, oxidative stress, and endothelial dysfunction: the Coronary Artery Risk Development in Young Adults (CARDIA)/Young Adult Longitudinal Trends in Antioxidants (YALTA) study,” Clinical Chemistry, vol. 53, no. 3, pp. 447–455, 2007. View at: Publisher Site | Google Scholar
  28. I. Sluijs, E. Cadier, J. W. J. Beulens, D. L. van der A, A. M. W. Spijkerman, and Y. T. van der Schouw, “Dietary intake of carotenoids and risk of type 2 diabetes,” Nutrition, Metabolism, and Cardiovascular Diseases, vol. 25, no. 4, pp. 376–381, 2015. View at: Publisher Site | Google Scholar
  29. K. Ylönen, G. Alfthan, L. Groop et al., “Dietary intakes and plasma concentrations of carotenoids and tocopherols in relation to glucose metabolism in subjects at high risk of type 2 diabetes: the Botnia Dietary Study,” The American Journal of Clinical Nutrition, vol. 77, no. 6, pp. 1434–1441, 2003. View at: Publisher Site | Google Scholar
  30. X.-R. Xu, Z.-Y. Zou, Y.-M. Huang, X. Xiao, L. Ma, and X. M. Lin, “Serum carotenoids in relation to risk factors for development of atherosclerosis,” Clinical Biochemistry, vol. 45, no. 16-17, pp. 1357–1361, 2012. View at: Publisher Site | Google Scholar
  31. M. S. Donaldson, “A carotenoid health index based on plasma carotenoids and health outcomes,” Nutrients, vol. 3, no. 12, pp. 1003–1022, 2011. View at: Publisher Site | Google Scholar
  32. P. Palozza, N. Parrone, R. E. Simone, and A. Catalano, “Lycopene in atherosclerosis prevention: an integrated scheme of the potential mechanisms of action from cell culture studies,” Archives of Biochemistry and Biophysics, vol. 504, no. 1, pp. 26–33, 2010. View at: Publisher Site | Google Scholar
  33. N. Di Pietro, P. Di Tomo, and A. Pandolfi, “Carotenoids in cardiovascular disease prevention,” JSM Atheroscler, vol. 1, pp. 1–13, 2016. View at: Google Scholar
  34. P. Di Fulvio, A. Pandolfi, G. Formoso et al., “Features of endothelial dysfunction in umbilical cord vessels of women with gestational diabetes,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 24, no. 12, pp. 1337–1345, 2014. View at: Publisher Site | Google Scholar
  35. R. Ambra, S. Manca, M. C. Palumbo et al., “Transcriptome analysis of human primary endothelial cells (HUVEC) from umbilical cords of gestational diabetic mothers reveals candidate sites for an epigenetic modulation of specific gene expression,” Genomics, vol. 103, no. 5-6, pp. 337–348, 2014. View at: Publisher Site | Google Scholar
  36. T. Peng, N.-K. Wong, X. Chen et al., “Molecular imaging of peroxynitrite with HKGreen-4 in live cells and tissues,” Journal of the American Chemical Society, vol. 136, no. 33, pp. 11728–11734, 2014. View at: Publisher Site | Google Scholar
  37. P. Di Tomo, R. Canali, D. Ciavardelli et al., “β-Carotene and lycopene affect endothelial response to TNF-α reducing nitro-oxidative stress and interaction with monocytes,” Molecular Nutrition & Food Research, vol. 56, no. 2, pp. 217–227, 2012. View at: Publisher Site | Google Scholar
  38. I. Castellano, P. di Tomo, N. di Pietro et al., “Anti-inflammatory activity of marine ovothiol A in an in vitro model of endothelial dysfunction induced by hyperglycemia,” Oxidative Medicine and Cellular Longevity, vol. 2018, Article ID 2087373, 12 pages, 2018. View at: Publisher Site | Google Scholar
  39. P. Di Tomo, P. Lanuti, N. Di Pietro et al., “Liraglutide mitigates TNF-α induced pro-atherogenic changes and microvesicles release in HUVEC from diabetic women,” Diabetes/Metabolism Research and Reviews, vol. 33, no. 8, article e2925, 2017. View at: Publisher Site | Google Scholar
  40. B. M. Leon and T. M. Maddox, “Diabetes and cardiovascular disease: epidemiology, biological mechanisms, treatment recommendations and future research,” World Journal of Diabetes, vol. 6, no. 13, article 1246, 1258 pages, 2015. View at: Publisher Site | Google Scholar
  41. R. S. Busch and M. P. Kane, “Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes,” Postgraduate Medicine, vol. 129, no. 7, pp. 686–697, 2017. View at: Publisher Site | Google Scholar
  42. J. S. Skyler, G. L. Bakris, E. Bonifacio et al., “Differentiation of diabetes by pathophysiology, natural history, and prognosis,” Diabetes, vol. 66, no. 2, pp. 241–255, 2017. View at: Publisher Site | Google Scholar
  43. P. Palozza, S. Serini, A. Torsello et al., “β-carotene regulates NF-κB DNA-binding activity by a redox mechanism in human leukemia and colon adenocarcinoma cells,” The Journal of Nutrition, vol. 133, no. 2, pp. 381–388, 2003. View at: Publisher Site | Google Scholar
  44. M. Paolini, A. Antelli, L. Pozzetti et al., “Induction of cytochrome P450 enzymes and over-generation of oxygen radicals in beta-carotene supplemented rats,” Carcinogenesis, vol. 22, no. 9, pp. 1483–1495, 2001. View at: Publisher Site | Google Scholar
  45. J. Virtamo, P. Pietinen, J. Huttunen et al., “Incidence of cancer and mortality following α-tocopherol and β-carotene supplementation: a postintervention follow-up,” JAMA, vol. 290, no. 4, pp. 476–485, 2003. View at: Publisher Site | Google Scholar
  46. A. J. Young and G. M. Lowe, “Antioxidant and prooxidant properties of carotenoids,” Archives of Biochemistry and Biophysics, vol. 385, no. 1, pp. 20–27, 2001. View at: Publisher Site | Google Scholar
  47. C. S. Boon, D. J. McClements, J. Weiss, and E. A. Decker, “Factors influencing the chemical stability of carotenoids in foods,” Critical Reviews in Food Science and Nutrition, vol. 50, no. 6, pp. 515–532, 2010. View at: Publisher Site | Google Scholar
  48. A. J. Meléndez-Martínez, I. M. Vicario, and F. J. Heredia, “Stability of carotenoid pigments in foods,” Archivos Latinoamericanos de Nutricion, vol. 54, no. 2, pp. 209–215, 2004. View at: Google Scholar
  49. C. Fortes and F. Virgili, “Antioxidant vitamins are not “just antioxidants”: not necessarily harmful when targeted to the right population,” BioFactors, vol. 33, no. 3, pp. 177–180, 2008. View at: Publisher Site | Google Scholar
  50. W. Baer-Dubowska, A. Bartoszek, and D. Malejka-Giganti, Carcinogenic and Anticarcinogenic Food Components, CRC Press, 2005.
  51. H. H. H. W. Schmidt, R. Stocker, C. Vollbracht et al., “Antioxidants in translational medicine,” Antioxidants & Redox Signaling, vol. 23, no. 14, pp. 1130–1143, 2015. View at: Publisher Site | Google Scholar
  52. M. M. Cortese-Krott, A. Koning, G. G. C. Kuhnle et al., “The reactive species interactome: evolutionary emergence, biological significance, and opportunities for redox metabolomics and personalized medicine,” Antioxidants & Redox Signaling, vol. 27, no. 10, pp. 684–712, 2017. View at: Publisher Site | Google Scholar
  53. T. Lawrence, “The nuclear factor NF-κB pathway in inflammation,” Cold Spring Harbor Perspectives in Biology, vol. 1, no. 6, article a001651, 2009. View at: Publisher Site | Google Scholar
  54. B. Pamukcu, G. Y. H. Lip, and E. Shantsila, “The nuclear factor – kappa B pathway in atherosclerosis: a potential therapeutic target for atherothrombotic vascular disease,” Thrombosis Research, vol. 128, no. 2, pp. 117–123, 2011. View at: Publisher Site | Google Scholar
  55. S. Patel and D. Santani, “Role of NF-κB in the pathogenesis of diabetes and its associated complications,” Pharmacological Reports, vol. 61, no. 4, pp. 595–603, 2009. View at: Publisher Site | Google Scholar
  56. M. Spiecker, H.-B. Peng, and J. K. Liao, “Inhibition of endothelial vascular cell adhesion molecule-1 expression by nitric oxide involves the induction and nuclear translocation of IκBα,” Journal of Biological Chemistry, vol. 272, no. 49, pp. 30969–30974, 1997. View at: Publisher Site | Google Scholar
  57. L. Sobrevia, D. L. Yudilevich, and G. E. Mann, “Elevated D-glucose induces insulin insensitivity in human umbilical endothelial cells isolated from gestational diabetic pregnancies,” The Journal of Physiology, vol. 506, no. 1, pp. 219–230, 1998. View at: Publisher Site | Google Scholar
  58. P. Pacher, J. S. Beckman, and L. Liaudet, “Nitric oxide and peroxynitrite in health and disease,” Physiological Reviews, vol. 87, no. 1, pp. 315–424, 2007. View at: Publisher Site | Google Scholar

Copyright © 2019 Mariangela Ucci et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1269 Views | 330 Downloads | 3 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.